Ping Tsui
Overview
Explore the profile of Ping Tsui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen K, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al.
PLoS One
. 2021 May;
16(5):e0252060.
PMID: 33999954
[This corrects the article DOI: 10.1371/journal.pone.0234268.].
2.
Allen K, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al.
PLoS One
. 2020 Jun;
15(6):e0234268.
PMID: 32497150
Annexin A1 (anxA1) is an immunomodulatory protein that has been proposed as a tumor vascular target for antitumor biologic agents, yet to date the vascular expression of anxA1 in specific...
3.
Li Q, Peterson N, Hanna R, Kuszpit K, White J, Allen K, et al.
Mol Pharm
. 2019 Dec;
17(2):507-516.
PMID: 31841002
Targeted strategies to deliver and retain drugs to kidneys are needed to improve drug accumulation and efficacy in a myriad of kidney diseases. These drug delivery systems show potential for...
4.
Li Q, Barrett A, Vijayakrishnan B, Tiberghien A, Beard R, Rickert K, et al.
Bioconjug Chem
. 2019 Mar;
30(4):1232-1243.
PMID: 30912649
Despite some clinical success with antibody-drug conjugates (ADCs) in patients with solid tumors and hematological malignancies, improvements in ADC design are still desirable due to the narrow therapeutic window of...
5.
Marchetti G, Burwell T, Peterson N, Cann J, Hanna R, Li Q, et al.
Commun Biol
. 2019 Mar;
2:92.
PMID: 30854484
Systemic administration of bio-therapeutics can result in only a fraction of drug reaching targeted tissues, with the majority of drug being distributed to tissues irrelevant to the drug's site of...
6.
Jack Borrok M, DiGiandomenico A, Beyaz N, Marchetti G, Barnes A, Lekstrom K, et al.
JCI Insight
. 2018 Jun;
3(12).
PMID: 29925682
IgG antibodies are abundantly present in the vasculature but to a much lesser extent in mucosal tissues. This contrasts with antibodies of the IgA and IgM isotype that are present...
7.
Li Q, White J, Peterson N, Rickert K, Lloyd C, Allen K, et al.
J Control Release
. 2018 Apr;
279:126-135.
PMID: 29653224
The accumulation, dissemination and clearance of monoclonal antibody-based therapeutics or imaging reagents targeting tumor associated antigens is governed by several factors including affinity, size, charge, and valency. Tumor targeting antibody...
8.
Jacobson O, Li Q, Chen H, Niu G, Kiesewetter D, Xu L, et al.
J Nucl Med
. 2017 May;
58(11):1838-1844.
PMID: 28546337
The erythropoietin-producing hepatoma A2 receptor (EphA2) is a tyrosine kinase overexpressed by tumor stroma and cancer cells. A high expression level of EphA2 predicts poor prognosis, correlating with disease progression...
9.
Jack Borrok M, Mody N, Lu X, Kuhn M, Wu H, DallAcqua W, et al.
J Pharm Sci
. 2017 Jan;
106(4):1008-1017.
PMID: 28057542
Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended...
10.
Tsui P, Higazi D, Wu Y, Dunmore R, Solier E, Kasali T, et al.
MAbs
. 2016 Nov;
9(1):104-113.
PMID: 27834568
Excessive transforming growth factor (TGF)-β is associated with pro-fibrotic responses in lung disease, yet it also plays essential roles in tissue homeostasis and autoimmunity. Therefore, selective inhibition of excessive and...